Nearly seven months after the early closeout of the pivotal Phase III study of Celacade in peripheral arterial disease, Vasogen Inc. reported that the product missed its primary endpoint in improving patients’ walking distance over placebo. (BioWorld Today)

Nearly seven months after the early closeout of the pivotal Phase III study of Celacade in peripheral arterial disease, Vasogen Inc. reported that the product missed its primary endpoint in improving patients’ walking distance over placebo. (BioWorld Today)

NPS Pharmaceuticals Inc. received an approvable letter for Preos, its parathyroid hormone to reduce fracture risk, but the company’s shares fell 37.5 percent amid safety concerns raised by the FDA. (BioWorld Today)

NPS Pharmaceuticals Inc. received an approvable letter for Preos, its parathyroid hormone to reduce fracture risk, but the company’s shares fell 37.5 percent amid safety concerns raised by the FDA. (BioWorld Today)